Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 1
1980 1
1982 1
1984 3
1985 3
1986 2
1987 2
1988 1
1989 2
1990 2
1998 1
1999 3
2001 1
2002 1
2008 1
2010 1
2011 1
2013 1
2014 1
2017 2
2018 1
2019 1
2020 1
2021 4
2022 5
2023 2
2024 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Non-coding RNA dysregulation in skin cancers.
Durante G, Comito F, Lambertini M, Broseghini E, Dika E, Ferracin M. Durante G, et al. Essays Biochem. 2021 Oct 27;65(4):641-655. doi: 10.1042/EBC20200048. Essays Biochem. 2021. PMID: 34414406
Circulating microRNA biomarkers in melanoma and non-melanoma skin cancer.
Durante G, Broseghini E, Comito F, Naddeo M, Milani M, Salamon I, Campione E, Dika E, Ferracin M. Durante G, et al. Expert Rev Mol Diagn. 2022 Mar;22(3):305-318. doi: 10.1080/14737159.2022.2049243. Epub 2022 Mar 11. Expert Rev Mol Diagn. 2022. PMID: 35235479 Review.
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary.
Cavazzoni A, Salamon I, Fumarola C, Gallerani G, Laprovitera N, Gelsomino F, Riefolo M, Rihawi K, Porcellini E, Rossi T, Mazzeschi M, Naddeo M, Serravalle S, Broseghini E, Agostinis F, Deas O, Roncarati R, Durante G, Pace I, Lauriola M, Garajova I, Calin GA, Bonafè M, D'Errico A, Petronini PG, Cairo S, Ardizzoni A, Sales G, Ferracin M. Cavazzoni A, et al. Among authors: durante g. Mol Ther. 2024 Oct 2;32(10):3650-3668. doi: 10.1016/j.ymthe.2024.07.011. Epub 2024 Jul 20. Mol Ther. 2024. PMID: 39033323 Free PMC article.
Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma.
Carrabotta M, Laginestra MA, Durante G, Mancarella C, Landuzzi L, Parra A, Ruzzi F, Toracchio L, De Feo A, Giusti V, Pasello M, Righi A, Lollini PL, Palmerini E, Donati DM, Manara MC, Scotlandi K. Carrabotta M, et al. Among authors: durante g. Cancer Res. 2022 Feb 15;82(4):708-720. doi: 10.1158/0008-5472.CAN-21-1222. Cancer Res. 2022. PMID: 34903601 Free PMC article.
Association of miR-146a-5p and miR-21-5p with Prognostic Features in Melanomas.
Naddeo M, Broseghini E, Venturi F, Vaccari S, Corti B, Lambertini M, Ricci C, Fontana B, Durante G, Pariali M, Scotti B, Milani G, Campione E, Ferracin M, Dika E. Naddeo M, et al. Among authors: durante g. Cancers (Basel). 2024 Apr 26;16(9):1688. doi: 10.3390/cancers16091688. Cancers (Basel). 2024. PMID: 38730639 Free PMC article.
Dysplastic nevi and melanoma: microRNAs tell a divergent story.
Durante G, Veronesi G, Misciali C, Riefolo M, Lambertini M, Tartari F, Ricci C, Ferracin M, Dika E. Durante G, et al. Pathol Res Pract. 2022 Jul;235:153942. doi: 10.1016/j.prp.2022.153942. Epub 2022 May 14. Pathol Res Pract. 2022. PMID: 35594599
49 results